Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?

Kidney Transplantation Clinical Trial

Official title:

Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00999362
• Other study ID #: TAC
• Status: Completed
• Phase: N/A
• First received: October 20, 2009
• Last updated: October 20, 2009
• Start date: October 2007
• Est. completion date: October 2009

Study information

• Verified date: October 2009
• Source: University of Aarhus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: The Regional Committee on Biomedical Research EthicsDenmark: Danish Dataprotection Agency
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether calcineurin phosphatase in the T-lymphocytes is up-regulated after long-term treatment with tacrolimus, a calcineurin inhibitor.

Description:

Background:

The immunosuppressive effect of both tacrolimus and cyclosporine is believed to be through inhibition of the enzyme calcineurin phosphatase (CaN) in T-lymphocytes. We have demonstrated, that tacrolimus decreases CaN activity in patients early after renal transplantation. In stable renal transplant patients treated this inhibition was hardly seen in patients treated with tacrolimus, while it was clearly demonstrated in patients treated cyclosporine. One explanation to this finding could be, that calcineurin phosphatase is up-regulated by long-term treatment with tacrolimus. The findings seem to imply, that tacrolimus has mechanisms of immunosuppression apart from inhibiting CaN. This could have implications for side-effects due to CaN inhibition. Among side-effects thought to be due to CaN inhibition is nephrotoxicity. The results may therefore be and indication of tacrolimus being less nephrotoxic compared to cyclosporine in long-term stable renal transplant patients.

Purpose:

The aim of the project is find out if long-term treatment with tacrolimus results in up-regulation of CaN in lymphocytes.

Study plan:

The general plan of the investigation is to compare CaN in lymphocytes in two groups of renal transplant patients treated with tacrolimus. One group just prior and just after transplantation compared to a group of stable renal transplanted patients a long time after transplantation. CaN is determined as enzyme activity, amount of protein, and by gen-activation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: October 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Group 1 (early kidney-transplant recipients)

• Age over 18 years

• 20 consecutively kidney-transplant recipients at Department of Nephrology, Aarhus University Hospital, Skejby, Denmark

• receiving tacrolimus as part of their immunosuppressive treatment

• receipt of graft from either deceased or living-related donor

• written consent to participate

Group 2 (stable kidney-transplant recipients)

• Age over 18 years

• Stable renal allograft function defined as S-creatinine <200 µmol/l

• variation in S-creatinine <20% for 6 months prior to inclusion

• kidney transplantation more than 2 years before inclusion

• receipt of graft from either deceased or living-related donor

• written consent to participate

Exclusion Criteria:

Group 1 (early kidney-transplant recipients)

• patients suspected of non-compliance

• patients receiving medications known to interact with tacrolimus pharmacokinetics

• patients who on day 8 after transplantation have not reached a trough level for blood tacrolimus concentration above 8 µg/l.

Group 2 (stable kidney-transplant recipients)

• patients suspected of non-compliance

• patients receiving medications known to interact with tacrolimus pharmacokinetics

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Kidney Transplantation

Locations

Country	Name	City	State
Denmark	Department of Nephrology, Aarhus University Hospital, Skejby	Aarhus

Sponsors (4)

Lead Sponsor	Collaborator
University of Aarhus	Astellas Pharma Inc, Danish Society of Nephrology, The Danish Kidney Association

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gene expression of calcineurin in T-lymphocytes		Trough level and 2 hours postdose	No
Primary	Calcineurin activity measured in whole blood and in isolated T-lymphocytes		Trough level and 2 hours postdose	No
Primary	Amount of Calcineurin in T-lymphocytes		Trough level and 2 hours postdose	No
Primary	Interferon-gamma production		Trough level and 2 hours postdose	No
Secondary	Tacrolimus concentration in whole blood		Trough level and 2 hours postdose	No
Secondary	Number of T-lymphocytes		Trough level and 2 hours postdose	No